not used title
not used title
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the unprecedented step of allowing the government to set the price of certain medicines in Medicare. Here’s a refresher on why the drug pricing provisions in the BBBA are bad policy.
Disincentivize further research after a medicine is approved. There appears to be a misconception that once a medicine is approved by the FDA, the work is done. In fact, many important lifesaving advancements have come from further research after a medicine is initially approved. Whether the research determines a medicine is also effective for different stages of a disease or a different condition altogether, the result of additional post-approval research is more patients can benefit from treatment. Despite this, the latest drug pricing plan targets medicines that have only been on the market for 7 years (small molecule medicine) or 11 years (biologics) – regardless of any additional indications the medicine has been approved for by the FDA. This guts any incentive for researchers to continue their critical work after a medicine is first approved.
Discourage development of generic and biosimilar medicines, which is key to driving competition in the United States. Congress created a carefully balanced system through Hatch-Waxman and the Biologics Price Competition and Innovation Act that encourages competition in the marketplace between brand medicines (both small molecules and biologics), generics and biosimilars. This system works to lower costs for patients and generates significant savings for the broader health care system while making room for additional critically needed innovation. In fact, more than 90% of all drugs dispensed at pharmacies in the United States are lower-cost generics, a number that exceeds other developed countries. But, under the latest drug pricing plan, medicines will be chosen for government price setting, in some cases, before a generic or biosimilar can even come to market. This would erode any incentive for manufacturers to invest in generic and biosimilar development.
Rely on government price setting, which has a history of causing restricted and delayed access to new medicines. Many countries in Europe implemented government price-setting mechanisms decades ago and patient access to medicines and investment in drug development have suffered. History shows that a government cannot interfere to dictate the price of medicines without negative consequences for patients. Adoption of government price setting and other anti-innovation policies across Europe in the 1980s and 1990s pushed R&D investment away from the continent to countries like the United States with more pro-innovation policies. That is why nearly 90% of new medicines launched globally since 2011 are available in the United States, compared to less than half, on average, in countries that allow the government to set prices.
Fail to meaningfully address the challenges patients have affording their medicines and instead makes a broken system worse. Today, many patients face high out-of-pocket costs and insurance barriers that restrict access to their medicines. That is not ok. But it is a problem that can and should be fixed. Unfortunately, the latest drug pricing plan is a missed opportunity to address the role middlemen, like pharmacy benefit managers, insurers and hospitals, play in forcing patients to pay more than they should for their medicine. Making sure patients share directly in the savings our industry provides, addressing insurance practices that restrict access to care and strengthening safety-net programs to ensure they deliver the support vulnerable patients need – these are real solutions that Congress should instead pursue.
Especially alarming is that neither chamber of Congress held hearings to debate and discuss the latest version of the drug pricing provisions included in the BBBA. Considering the significant negative consequences this plan poses to patients and our innovation ecosystem, it is irresponsible to move forward with it.
With the new year, Congress should take the opportunity to reconsider whether policies that threaten access to future treatments and cures are the right approach.
Tell Congress to protect Medicare and focus on commonsense solutions that will help people access and afford their medicines.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
Author Twitter
Author LinkedIn
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Voters continue to voice their concerns on government price controls
July 24, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
Guest Blog: Price controls won’t lower costs when insurers control access
June 25, 2026
MFN could disrupt the affordable medicines patients depend on
June 18, 2026
New “America Cures” ad: U.S. patients get new medicines first
June 15, 2026
Patients speak out: MFN won't address my affordability concerns
June 4, 2026
MFN price controls threaten American jobs and the U.S. economy
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
State price-setting boards create more questions than answers
May 20, 2026
New analysis highlights access to new medicines in the United States and abroad
May 13, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
MFN price controls would drain pensions and put retirements at risk
April 23, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
CMS undermines medical progress with MFN price controls
April 16, 2026
Trump Administration’s efforts to have other countries pay their fair share are underway
April 15, 2026
CMS’ MFN proposals won’t help seniors despite lofty promises
April 9, 2026
Voters voice concerns on government price controls
April 7, 2026
Virginia should be cautious about importing federal price-setting mechanisms
April 1, 2026
Policymakers shouldn’t double down on the IRA’s flaws with MFN
March 30, 2026
Insurers routinely block seniors’ access to medicines in Medicare Part D
March 18, 2026
MFN drug pricing risks reviving a harmful metric the U.S. rejected
March 16, 2026
Leadership in biopharmaceutical R&D provides U.S. patients the greatest access to innovative medicines
March 11, 2026
Harmful U.S. policies will help drive China’s global leadership in biopharmaceutical innovation
March 4, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
Guest blog: Making the most of the Medicare Prescription Payment Plan
December 8, 2025
Myth vs. Fact: How government price setting impacts innovation
November 24, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
PhRMA calls on USTR to ensure foreign nations pay their fair share
November 4, 2025
What seniors can expect this open enrollment
October 14, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
Delivering breakthroughs and lower costs for patients
September 8, 2025
Celebrating 60 Years of Medicare
July 30, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
CMS continues to make a bad law worse
June 27, 2025
ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices
June 26, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas
June 16, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
PBMs launch new ad campaign to block reforms
May 5, 2025
New analysis: Fewer treatments and cures under the IRA’s pill penalty
May 1, 2025
How the IRA is impacting the generic drug market
April 8, 2025
Three reasons Congress should fix the IRA’s pill penalty
March 24, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
CMS, don’t fall behind the rest of the medical community on obesity
February 14, 2025
Virginia, Don't Let Politicians Take Away Your Medicine
January 23, 2025
Patients are losing as government price setting continues
January 17, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
Reimagining patient access through meaningful policy reform
November 5, 2024
CMS needs to do better
November 4, 2024
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
October 30, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
7 reasons why states shouldn’t copy the IRA’s price setting mistake
October 15, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
Three ways state drug price setting boards fail patients
September 18, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
Did the administration consider the importance of autoimmune disease medicines to patients in price setting process?
September 11, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Biosimilars continue to drive market competition and increase savings for seniors
August 6, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
How the IRA is more coercive than any European government price setting scheme
May 29, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
How government price setting fails to address systemic health care inequities
May 24, 2024
Ongoing federal probes shed light on PBM and insurer practices
May 20, 2024
Government price-setting boards: Why Minnesota needs to take a better approach
May 9, 2024
WTAS: The consequences of consolidation and vertical integration
May 6, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Insurance data: PBM reform has no material impact on premiums
April 24, 2024
Government price setting won’t help patients in Illinois
April 22, 2024
New study finds insurers and PBMs increasing access restrictions in Medicare Part D
April 16, 2024
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
April 11, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
Colorado is proof: Too many unanswered questions remain about state government price setting's impact on patients and providers
March 14, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
The truth about Nebraska's price setting push
February 13, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
Biosimilars drive savings, but the IRA undermines their development
December 14, 2023
ICYMI: When middlemen get in the way, it’s the patients who lose
December 5, 2023
New analysis of patient access restrictions in the United Kingdom
November 21, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
Don't close the door on rare disease research
November 13, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
One year to Election Day: Four voter priorities to watch
November 6, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Three things economists are saying about the Inflation Reduction Act
October 11, 2023
4 truths about state government price setting
October 10, 2023
ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs
September 28, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
Medicare Prescription Payment Plan will benefit patients if implemented correctly
September 21, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
Three concerns about Colorado's approach to government price setting
August 23, 2023
With the first list of medicines out, let’s not forget why government price setting is bad policy
August 22, 2023
Michigan proposal jeopardizes access to medicines
August 21, 2023
One year later IRAs unintended consequences are becoming reality
August 16, 2023
AARP’s latest misleading report
August 11, 2023
Three things to know from the latest Patient Experience Survey
July 20, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
June 22, 2023
ASCO 2023: Protecting our progress in the fight against cancer
June 15, 2023
Highlights from ASCO 2023
June 8, 2023
Four things for CMS to keep in mind as they implement changes to Part D
June 7, 2023
ICYMI: PBM exec admits choosing profits over patients
June 2, 2023
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
May 30, 2023
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
May 11, 2023
4 key facts on medicine prices and spending
May 9, 2023
Support for continued progress is critical for pediatric drug development
May 8, 2023
4 Things to know about PhRMA’s new 50-state poll
May 4, 2023
New resource underscores the importance of small molecule medicines
May 4, 2023
Americans want state policymakers to lower out-of-pocket costs
May 1, 2023
Three facts about health care spending
April 25, 2023
CMS guidance on IRA price setting process doubles down on bad policy
April 14, 2023
A guide to MedPAC’s Part B vote today
April 13, 2023
New global analysis shows patient access challenges around the world
April 12, 2023
ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability
April 7, 2023
MedPAC proposal threatens access to medicines in Part B
April 6, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
CMS coverage policy is detrimental to Alzheimer’s patients
April 4, 2023
How Part B’s ASP system helps control costs for the government and seniors
March 30, 2023
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
March 29, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
Medicare Part B spending in four points
March 28, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
IRA Impacts: Cancer treatment research and development
March 23, 2023
Celebrating 40 years of the Orphan Drug Act on Rare Disease Day
February 28, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
Senate hearing to examine bipartisan reforms to rein in middlemen
February 16, 2023
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
January 31, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
WTAS: Inflation Reduction Act already impacting R&D decisions
January 17, 2023
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
In their own words: Financial barriers exacerbate access challenges for insured Americans
December 8, 2022
Putting Delaware patients first: Protecting Patient Assistance Programs
November 22, 2022
Medicare Part D open enrollment and what recent changes mean for beneficiaries
November 17, 2022
New data show how insurers and middlemen shift Rx costs onto patients
November 16, 2022
New government price setting policy threatens post-approval research
November 10, 2022
In their own words: Insured Americans struggle to navigate complex coverage
October 26, 2022
Many seniors are paying more for Part D medicines than their insurer
October 18, 2022
Biosimilar uptake is increasing and so are health savings
October 17, 2022
New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance
October 7, 2022
Busting 3 Myths About Copay Coupons
October 5, 2022
Mental Illness Awareness Week – A time for reflection
October 3, 2022
A key fact the White House is reluctant to admit
September 27, 2022
A key fact the White House is reluctant to admit
September 27, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
Rejecting ICER’s bad advice
September 9, 2022
CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease
September 1, 2022
Making coupons count for patients at the pharmacy counter
August 25, 2022
New survey: Voters seriously concerned about fine print in reconciliation bill
August 12, 2022
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
August 10, 2022
Making coupons count for patients with HIV
August 8, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
An open letter to Congress: Stand with patients and future cures
August 4, 2022
ICYMI: Patients across the country are sharing concerns about government price setting
August 3, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
August 1, 2022
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
July 29, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: American medical innovation
July 27, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022